4DMedical (ASX:4DX) has secured $30.2 million in funding by entering an underwriting agreement with Bell Potter Securities, ensuring the full exercise of its 4DXO listed options.
Under the agreement, any unexercised options at expiry will be subscribed by the underwriter, guaranteeing the total funding amount.
To date, approximately 8 million of the 22.2 million options have been exercised, leaving 14.2 million underwritten options valued at around $19.3 million.
With the additional funds, 4DMedical’s pro forma cash balance as of Sept. 30 stands at $63.7 million.
The underwriter, not a related party, will receive a 2.5% fee on the underwritten amount.
4DMedical's MD/CEO Andreas Fouras said the funding positions the company strongly to advance its CT:VQ technology, with multiple contract discussions underway.
"This agreement ensures we have more than sufficient capital to execute our plans to commercialise CT:VQ and lead the company through to profitability," he said, highlighting 2026 as a potentially transformational year for the business.